The nonsteroidal anti-inflammatory drug (NSAID) flunixin meglumine has been approved by the FDA for fever associated with ...

Nonsteroidal anti-inflammatory drug use for over 2 years was associated with a lower risk for dementia, especially ...

with placebo or other nonsteroidal anti-inflammatory drugs (NSAIDs). Overall, the efficacy of meloxicam was significantly superior to that of placebo and similar to that of other NSAIDs ...

The American College of Physicians (ACP) has developed new recommendations for treatment of acute episodic migraines in nonpregnant adults in outpatient settings.

Long-term nonsteroidal anti-inflammatory drug (NSAID) use is associated with reduced dementia risk, according to a ...

The FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on Monday. Approval of the topical aryl hydrocarbon receptor agonist was ...

Meloxicam is well absorbed after oral administration, with an absolute bioavailability of 89% that is not markedly affected by concomitant intake of food. Meloxicam reaches maximum plasma ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...